49
49
Jul 31, 2014
07/14
by
CSPAN3
tv
eye 49
favorite 0
quote 0
mr. gingrey talk about members of congress and members of the administration should take same thing people have to take. i agree with that. in fact, i did not take the bc exchange that was offer to members of congress and their staff. i said, look, i'll do what other people in my district have to do. i went to healthcare.gov, bought a bronze plan off the website, biggest mess i've ever been involved in in my life. but i finally got through, took about 3 1/2 months to do so. now i'm wondering what my rate is going to be next year. i've got the most expensive insurance health insurance policy i've ever had and enormous deductible. but what can i look forward to in the next insurance year? you talked about you wanted asea successful open enrollment? is it going to be successful? what are rates going to look like? >> so i think we're at a stage now where, and, indeed, this is one of our high measures for success, making sure there is enough choices and enough affordability and, of course, each state is going through their own process and going through rate reviews. we have seen some states pub
mr. gingrey talk about members of congress and members of the administration should take same thing people have to take. i agree with that. in fact, i did not take the bc exchange that was offer to members of congress and their staff. i said, look, i'll do what other people in my district have to do. i went to healthcare.gov, bought a bronze plan off the website, biggest mess i've ever been involved in in my life. but i finally got through, took about 3 1/2 months to do so. now i'm wondering...
44
44
Jul 30, 2014
07/14
by
CSPAN
tv
eye 44
favorite 0
quote 0
mr. sessions: at this time, i would like to yield two minutes to the gentleman from georgia, dr. gingrey. the speaker pro tempore: the gentleman is recognized for two minutes. mr. gingrey: i rise today in support of h.res. 676, a resolution to authorize the house of representatives to initiate litigation against the president or any executive branch employee for failure to act in accordance with their duties. specifically, this resolution deal with the president's failure to implement the employee mandate required by his own signature law, the patient protection and affordable care act. while the scope of the litigation authorizes is narrow, it is symbolic of a much larger problem, the president's continued refusal to execute the congress'ing to usurp constitutional right to legislate. simply because congress chooses not to be the president's rubber stamp does not bestow upon him the power to circumvent the law. conversely when the president says it might be politically perilous, he can't simply choose to ignore it. mr. speaker, this is not about party politics, this is about the proper
mr. sessions: at this time, i would like to yield two minutes to the gentleman from georgia, dr. gingrey. the speaker pro tempore: the gentleman is recognized for two minutes. mr. gingrey: i rise today in support of h.res. 676, a resolution to authorize the house of representatives to initiate litigation against the president or any executive branch employee for failure to act in accordance with their duties. specifically, this resolution deal with the president's failure to implement the...
68
68
Jul 24, 2014
07/14
by
CSPAN
tv
eye 68
favorite 0
quote 0
mr. gingrey of georgia for today and the balance of the week. the speaker pro tempore: without objection, the request s granted. under the speaker's announced policy of january 3, 2013, the gentleman from texas, mr. gohmert, is recognized for 60 minutes as the designee of the majority leader. mr. gohmert: thank you, mr. speaker. it is my distinct honor to recognize a friend, a colleague, a guy i came in with in the class of 2004, my friend, mr. fortenberry, for all the time he may use. mr. fortenberry: i thank the gentleman from texas, my good friend, congressman gohmert. i appreciate you yielding the time. i appreciate your willingness to engage in the most important dialogue facing our nation night after night and thank you, again, for allowing me to intrude a bit on your time. but i wanted to raise something . utmost urgency, mr. speaker mosul is iraq's second largest city, and for 1,600 years, mosul has been a center of christian life. and today not a single christian remains. now, who could have imagined that one month ago, just a month ago,
mr. gingrey of georgia for today and the balance of the week. the speaker pro tempore: without objection, the request s granted. under the speaker's announced policy of january 3, 2013, the gentleman from texas, mr. gohmert, is recognized for 60 minutes as the designee of the majority leader. mr. gohmert: thank you, mr. speaker. it is my distinct honor to recognize a friend, a colleague, a guy i came in with in the class of 2004, my friend, mr. fortenberry, for all the time he may use. mr....
93
93
Jul 17, 2014
07/14
by
CSPAN3
tv
eye 93
favorite 0
quote 0
gingrey did you want to introduce somebody from your district? >> mr. for giving me the opportunity. i know this witness is on the second panel and it will be a little while before we'll be hearing from the second panel, but it is an honor and a pleasure to introduce off of the second panel shawn kaufman. mr. kaufman is president and founding partner of a company called behavioral based improvement solutions. his background is long-term employment with the cdc before forming his own company in my district, the 11th congressional district of georgia in woodstock, georgia. and i would encourage all of the members on both sides of the aisle if you haven't had a chance, we try to read all of the testimony, but sometimes we skip one or two along the way. but i will assure you that the written testimony from mr. kaufman really hits the nail right on the head in regard to this overall issue. and i would commend it to you. and i am proud to introduce him to you in anticipation of the second panel. mr. chairman, thank you. i yield back. >> to the panel, you are
gingrey did you want to introduce somebody from your district? >> mr. for giving me the opportunity. i know this witness is on the second panel and it will be a little while before we'll be hearing from the second panel, but it is an honor and a pleasure to introduce off of the second panel shawn kaufman. mr. kaufman is president and founding partner of a company called behavioral based improvement solutions. his background is long-term employment with the cdc before forming his own...
44
44
Jul 22, 2014
07/14
by
CSPAN2
tv
eye 44
favorite 0
quote 0
gingrey for five minutes for questions. >> mr. chairman, thank you. and i'm going to address my questions to this panel to dr. frieden. dr. frieden, thank you very much for being here and providing the subcommittee with your testimony. i actually have a number of questions for you, in fact, four, and i'll get right to those since time is of the essence. firstly, can you leads describe the -- please describe the oils and procedures cdc has in place to handle biosafety issues that may arise from human error like what happened in the bioterrorrism rapid response and advance technology laboratory in atlanta on june the 5th? >> we have extensive policies and procedures, but what we are doing now is implementing a moratorium on all transfers out of bsl3 and bsl4 laboratories while we review each lab laboratory's policy and procedure to insure there's an appropriate activation before any materials are transferred out. >> and i appreciate that answer, and you explained that to us, i think, last week in an informal setting, and i think that's a good thing. tha
gingrey for five minutes for questions. >> mr. chairman, thank you. and i'm going to address my questions to this panel to dr. frieden. dr. frieden, thank you very much for being here and providing the subcommittee with your testimony. i actually have a number of questions for you, in fact, four, and i'll get right to those since time is of the essence. firstly, can you leads describe the -- please describe the oils and procedures cdc has in place to handle biosafety issues that may arise...
48
48
Jul 11, 2014
07/14
by
CSPAN2
tv
eye 48
favorite 0
quote 0
gingrey. for five minutes for questions. >> mr. chairman, thank you. dr. woodcock, thank you for appearing.always good to see you. i understand that a number of the challenges that have led to the duration and cost of conducting clinical trials in the u.s. to increase essentially are outside of fda's per view. that being said, clinical trials are conducted to generate evidence used in the application for fda approval. so how early, my question is, my first question, how early do you typically communicate with these companies, pharmaceutical companies, to discuss their trial design before the visional of a new drug application is submitted? >> well, we have agreements under pdfa that prescription drug user fee program. testing a disease that really doesn't have any treatment. companies can come in with a premeeting. that is meeting is before they start the their clinical trials, first in human studies and we talk about that development program so they can start thinking how that is going to be done. we do have information, it is preliminary, but looking at our information, it seems that comp
gingrey. for five minutes for questions. >> mr. chairman, thank you. dr. woodcock, thank you for appearing.always good to see you. i understand that a number of the challenges that have led to the duration and cost of conducting clinical trials in the u.s. to increase essentially are outside of fda's per view. that being said, clinical trials are conducted to generate evidence used in the application for fda approval. so how early, my question is, my first question, how early do you...
76
76
Jul 17, 2014
07/14
by
CSPAN3
tv
eye 76
favorite 0
quote 0
gingrey for five minutes for questions. >> mr. chairman, thank you. i'm going to address my questions of this foonl dr. frieden. thank you very much for being here and providing the subcommittee with your testimony. i actually have a number of questions for you. in fact, four. and i'll get right to those since time is of the essence. firstly, can you please describe the policies and procedures cdc has in place to handle biosafety issues that may arise from human error? like what happened in the bioterrorism rapid response and advance technology laboratory in atlanta on june the 5th. >> we have extensive policies and procedures but what we are doing now is implementing a moratorium on all transfers out of bsl 3 and bsl 4 laboratories while we review each laboratory's policies and procedures to ensure that there's appropriate inactivation before any materials of transferred out. >> i appreciate that answer. and you explained that to us last week. an informal setting. i think that's a good thing. that leads to my second question. what is the impact and t
gingrey for five minutes for questions. >> mr. chairman, thank you. i'm going to address my questions of this foonl dr. frieden. thank you very much for being here and providing the subcommittee with your testimony. i actually have a number of questions for you. in fact, four. and i'll get right to those since time is of the essence. firstly, can you please describe the policies and procedures cdc has in place to handle biosafety issues that may arise from human error? like what happened...